Nurix Therapeutics, Inc.

Equities

NRIX

US67080M1036

Market Closed - Nasdaq Other stock markets 02:30:00 23/01/2026 am IST			5-day change	1st Jan Change
19.39 ^USD	+1.95%		+2.81%	+2.21%

20/01	RBC Trims Price Target on Nurix Therapeutics to $28 From $29, Keeps Outperform, Speculative Risk	MT
13/01	Nurix Therapeutics, Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-12-2026 04:30 PM

Transcript : Nurix Therapeutics, Inc. - Special Call

Published on 12/09/2025 at 09:35 am IST - Modified on 12/09/2025 at 02:50 pm IST

S&P Capital IQ

Presenter Speech
Arthur Sands (Executives)

Good evening, everyone. My name is Arthur Sands. I'm President and CEO of Nurix Therapeutics. And I'd like to welcome you to our 2025 Investor and Analyst

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Nurix Therapeutics, Inc.

20/01	RBC Trims Price Target on Nurix Therapeutics to $28 From $29, Keeps Outperform, Speculative Risk	MT
13/01	Nurix Therapeutics, Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-12-2026 04:30 PM
08/01	Morgan Stanley Upgrades Nurix Therapeutics to Overweight From Equal Weight, Raises Price Target to $36 From $15	MT
22/12	Certain Pre-funded Warrants of Nurix Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 22-DEC-2025.	CI
22/12	Certain Restricted Stock Units of Nurix Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 22-DEC-2025.	CI
22/12	Certain Stock Options of Nurix Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 22-DEC-2025.	CI
22/12	Certain Common Stock of Nurix Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 22-DEC-2025.	CI
10/12	Mizuho Adjusts Price Target on Nurix Therapeutics to $30 From $24, Maintains Outperform Rating	MT
09/12	Nurix Therapeutics, Inc. - Special Call
08/12	Nurix Therapeutics presents new data from the phase 1 trial of bexobrutideg in Waldenström macroglobulinemia at the 67th American Society of Hematology annual meeting and exposition	RE
06/12	Nurix Therapeutics, Inc. Presents New Data Demonstrating Durable, Deepening Responses in Phase 1 Trial of Bexobrutideg (NX-5948) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia at the 67th American Society of Hematology Annual Meeting & Exposition	CI
28/11	Nurix Therapeutics, Inc. Presents at Stifel 2025 Healthcare Conference, Nov-13-2025 09:20 AM
28/11	Nurix Therapeutics, Inc. Presents at Jefferies London Healthcare Conference 2025, Nov-19-2025 11:00 AM
10/11	Nurix Therapeutics, Inc. Appoints Roger Dansey to Its Board of Directors	CI
07/11	Nurix Therapeutics presents new translational data from first-in-human clinical trial of oral CBL-B inhibitor NX-1607 demonstrating immune activation and tumor microenvironment remodeling	RE
07/11	Nurix Therapeutics, Inc. Presents New Translational Data from First-In-Human Clinical Trial of Oral CBL-B Inhibitor	CI
27/25/27	Nurix Therapeutics Closes $250 Million Underwritten Public Stock Offering	MT
23/25/23	RBC Raises Price Target on Nurix Therapeutics to $29 From $28, Keeps Outperform, Speculative Risk	MT
22/25/22	Nurix Therapeutics, Inc. Initiates Daybreak Pivotal Study of Bexobrutideg in Relapsed or Refractory Chronic Lymphocytic Leukemia	CI
22/25/22	Nurix Therapeutics, Inc. - Special Call
22/25/22	Nurix Therapeutics Prices $250 Million Registered Common Stock Offering	MT
21/25/21	Mizuho Initiates Nurix Therapeutics at Outperform With $24 Price Target	MT
18/25/18	Nurix Therapeutics Reports New Clinical Data from First-In-Class Oral CBL-B Inhibitor, NX-1607, Demonstrating Single-Agent Activity Across Multiple Tumor Types at the European Society for Medical Oncology Congress	CI
10/25/10	Sector Update: Health Care Stocks Advance Premarket Friday	MT
10/25/10	Exchange-Traded Funds, Equity Futures Higher Pre-Bell as Investors Eye Consumer Sentiment Report	MT